Brandi L. Roberts serves as Chief Financial Officer at Definium Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic diseases. With more than 20 years of experience in finance within the biotechnology and pharmaceutical sectors, Brandi brings a wealth of expertise in strategic financial planning, capital raising, and operational optimization. She earned her Bachelor of Science in Accounting from the University of Utah and an MBA from Brigham Young University, laying a strong foundation for her distinguished career. Prior to joining Definium in 2022, Brandi held senior finance roles at several prominent biotech firms, including Vice President of Finance at Ardelyx, Inc., where she spearheaded financial operations during a pivotal Phase 3 trial and NASDAQ IPO, raising over $200 million in equity financing. Her achievements also include leading treasury management and investor relations at BioDelivery Sciences International, contributing to multiple successful debt financings and mergers that enhanced shareholder value. Recognized for her ability to navigate complex regulatory landscapes and market volatilities, Brandi has consistently delivered sustainable growth in resource-constrained environments. At Definium Therapeutics, Brandi oversees all financial aspects, including budgeting, forecasting, and securing non-dilutive funding to support the company's lead asset, DF-002, through ongoing clinical development. Her strategic leadership has been instrumental in forging key partnerships and positioning the company for long-term success in addressing unmet needs in metabolic disorders.